Clinical Trials Directory

Trials / Completed

CompletedNCT02310425

A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
125 (actual)
Sponsor
Lingfen Xu, MD · Academic / Other
Sex
All
Age
28 Days
Healthy volunteers
Accepted

Summary

Immature gastrointestinal functions increase the risk of poor growth as well as nosocomial infections and necrotizing enterocolitis (NEC) in the preterm infant. The effects of probiotics on growth and development in premature infants have been investigated poorly. Saccharomyces boulardii CNCM I-745 (S. boulardii) is a non-pathogenic probiotic yeast. Prophylactic supplementation of S. boulardii at a dose of 50 mg/kg twice a day appeared to bring preterm infants weight gain closer to that of intra-uterine growth rate, reduce feeding intolerance, and had no adverse effects.

Detailed description

The objective of this study is to evaluate if feeding supplemented with S. boulardii can improve growth and clinical outcomes in preterm and low birth weight infants. A prospective, randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g. The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group. The primary outcomes were short term growth parameters including weight gain, linear growth, head and chest circumference, and secondary outcomes were clinical outcomes, feeding intolerance and complications. A total of 125 infants were enrolled in the study, 63 in the treatment and 62 in the control group. S. boulardii was administered for the first time at 2.63 days after birth (1 day to 6 days, 46 within 3 days, only 5 between 4 and 6 days).

Conditions

Interventions

TypeNameDescription
DRUGS. boulardii50 mg/kg twice daily
DRUGPlacebohe control group (group C) did not receive S. boulardii (nor other probiotics)

Timeline

Start date
2013-03-01
Primary completion
2013-07-01
Completion
2014-01-01
First posted
2014-12-08
Last updated
2014-12-08

Source: ClinicalTrials.gov record NCT02310425. Inclusion in this directory is not an endorsement.